GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, today announced the appointment of Dr. Jingrong Li as Chief Technology Officer. Dr. Li will be responsible for GenFleet’s pharmaceutical development and quality control platform, as well as building out the company’s GMP manufacturing capabilities to support global regulatory registration and commercialization of innovative therapeutic programs.
In addition, Dr. Li will serve as general manager of GenFleet Biologics to lead the R&D and manufacturing efforts of GenFleet’s biologic pipeline. Dr. Li will also direct the construction of GenFleet’s 70,000 square meters biologics manufacturing site in Shanghai’s Lingang New Town, as part of company’s commercialization strategy for innovative therapies.
Bringing in over two decades of experiences in the pharmaceutical industry, Dr. Li was involved in numerous programs of approved drugs and diagnostics. His expertise ranges from process development, quality control validation, scale-up manufacturing to other core technologies related with the upstream & downstream sectors of the industry and led various teams to develop preclinical and clinical batches of different monoclonal antibodies, therapeutic vaccines and recombinant protein products.
Prior to GenFleet, Dr. Li was the Chief Technology Officer of CStone Pharmaceuticals and the manager principal scientist of Roche Molecular Systems; besides, he also worked in Simcere and BSK Bio.
He received his doctorate degree in China Pharmaceutical University and completed post-doctoral training at Mount Sinai Medical Center in New York. Dr. Li was a professor at China Pharmaceutical University and the distinguished expert of National Medical Products Administration Institute of Executive Development.
“I am delighted to join GenFleet while the company is at a critical inflection point of commercialization. I hope to contribute to the development of biologics and the commercial production of innovative therapies as GenFleet continue to achieve more milestones in future. “said Jingrong Li, Ph.D., Chief Technology Officer of GenFleet Therapeutics.
“With an emphasis in MOA-driven research, GenFleet has built industry leading pipeline of both small molecules and biologics and the company is transitioning from a clinical-stage biotech to commercialization. We are excited to welcome Dr. Li as our Chief Technology Officer, with his wealth of experiences in both R&D and manufacturing, we look forward to the synergy between GenFleet’s different research functions with our newly established manufacturing platforms, and further propel the development of GenFleet’s leading-edge pipeline.” Jiong Lan, Ph.D., Chief Executive Officer of GenFleet Therapeutics.
